Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1336

1.

CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma.

Sakamoto Y, Fujii K, Murase S, Nakano S, Masaki A, Murase T, Kusumoto S, Iida S, Utsunomiya A, Ueda R, Ishida T, Inagaki H.

Int J Hematol. 2019 Oct;110(4):389-392. doi: 10.1007/s12185-019-02728-5. Epub 2019 Aug 29.

PMID:
31468320
2.

Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma.

Maekawa K, Ri M, Nakajima M, Sekine A, Ueda R, Tohkin M, Miyata N, Saito Y, Iida S.

Cancer Sci. 2019 Aug 23. doi: 10.1111/cas.14178. [Epub ahead of print]

3.

Observing brain function via functional near-infrared spectroscopy during cognitive program training (dual task) in young people.

Techayusukcharoen R, Iida S, Aoki C.

J Phys Ther Sci. 2019 Jul;31(7):550-555. doi: 10.1589/jpts.31.550. Epub 2019 Jul 9.

4.

Plasma cell myeloma positive for t(14;20) with relapse in the central nervous system.

Murase T, Inagaki A, Masaki A, Fujii K, Narita T, Ri M, Hanamura I, Iida S, Inagaki H.

J Clin Exp Hematop. 2019 Aug 8. doi: 10.3960/jslrt.19011. [Epub ahead of print]

5.

Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.

Dimopoulos MA, Moreau P, Iida S, Huang SY, Takezako N, Chng WJ, Zahlten-Kumeli A, Sersch MA, Li J, Huang M, Lee JH.

Int J Hematol. 2019 Oct;110(4):466-473. doi: 10.1007/s12185-019-02704-z. Epub 2019 Aug 6.

PMID:
31388932
6.

When and why do trees begin to decrease their resource allocation to apical growth? The importance of the reproductive onset.

Suzuki M, Umeki K, Orman O, Shibata M, Tanaka H, Iida S, Nakashizuka T, Masaki T.

Oecologia. 2019 Sep;191(1):39-49. doi: 10.1007/s00442-019-04477-y. Epub 2019 Aug 1.

PMID:
31372895
7.

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study.

Iida S, Watanabe T, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Tobinai K.

Cancer Sci. 2019 Sep;110(9):2924-2932. doi: 10.1111/cas.14139. Epub 2019 Aug 10.

8.

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.

Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators.

Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.

PMID:
31327687
9.

Depressive symptoms during the first month of chemotherapy and survival in patients with hematological malignancies: A prospective cohort study.

Hasegawa T, Okuyama T, Uchida M, Aiki S, Imai F, Nishioka M, Suzuki N, Iida S, Komatsu H, Kusumoto S, Ri M, Osaga S, Akechi T.

Psychooncology. 2019 Aug;28(8):1687-1694. doi: 10.1002/pon.5143. Epub 2019 Jul 2.

PMID:
31267595
10.

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.

Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O' Rourke L, Dimopoulos MA.

Haematologica. 2019 Jun 20. pii: haematol.2019.217448. doi: 10.3324/haematol.2019.217448. [Epub ahead of print]

11.

Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma.

Murase T, Ri M, Narita T, Fujii K, Masaki A, Iida S, Inagaki H.

Cancer Sci. 2019 Aug;110(8):2600-2606. doi: 10.1111/cas.14109. Epub 2019 Jul 11.

12.

Intermittent parathyroid hormone 1-34 induces oxidation and deterioration of mineral and collagen quality in newly formed mandibular bone.

Yoshioka Y, Yamachika E, Nakanishi M, Ninomiya T, Akashi S, Kondo S, Moritani N, Kobayashi Y, Fujii T, Iida S.

Sci Rep. 2019 May 29;9(1):8041. doi: 10.1038/s41598-019-44389-8.

13.

Generation of Yellow Flowers of the Japanese Morning Glory by Engineering Its Flavonoid Biosynthetic Pathway toward Aurones.

Hoshino A, Mizuno T, Shimizu K, Mori S, Fukada-Tanaka S, Furukawa K, Ishiguro K, Tanaka Y, Iida S.

Plant Cell Physiol. 2019 Aug 1;60(8):1871-1879. doi: 10.1093/pcp/pcz101.

PMID:
31135027
14.

Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma.

Yoshida T, Ri M, Fujinami H, Oshima Y, Tachita T, Marumo Y, Sasaki H, Kinoshita S, Totani H, Narita T, Masaki A, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S.

Int J Hematol. 2019 Aug;110(2):228-236. doi: 10.1007/s12185-019-02669-z. Epub 2019 May 22.

PMID:
31119611
15.

Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma.

Ashour R, Ri M, Aly SS, Yoshida T, Tachita T, Kanamori T, Aoki S, Kinoshita S, Narita T, Totani H, Masaki A, Ito A, Kusumoto S, Komatsu H, Mansour S, Elsaied AA, Iida S.

Int J Hematol. 2019 Jul;110(1):69-76. doi: 10.1007/s12185-019-02649-3. Epub 2019 May 21.

PMID:
31115879
16.

Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study).

Moreau P, Kumar S, Boccia R, Iida S, Goldschmidt H, Cocks K, Trigg A, Zahlten-Kumeli A, Yucel E, Panjabi SS, Dimopoulos M.

Leukemia. 2019 May 15. doi: 10.1038/s41375-019-0480-2. [Epub ahead of print]

PMID:
31092895
17.

Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.

Yamazaki H, Shirakawa K, Matsumoto T, Hirabayashi S, Murakawa Y, Kobayashi M, Sarca AD, Kazuma Y, Matsui H, Maruyama W, Fukuda H, Shirakawa R, Shindo K, Ri M, Iida S, Takaori-Kondo A.

Sci Rep. 2019 May 9;9(1):7122. doi: 10.1038/s41598-019-43575-y.

18.

[Multiple myeloma: MM].

Iida S.

Rinsho Ketsueki. 2019;60(3):251-253. doi: 10.11406/rinketsu.60.251. Japanese. No abstract available.

PMID:
31068535
19.

Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.

Suzuki Y, Saito M, Ishii T, Urakawa I, Matsumoto A, Masaki A, Ito A, Kusumoto S, Suzuki S, Hiura M, Takahashi T, Morita A, Inagaki H, Iida S, Ishida T.

Clin Cancer Res. 2019 Jul 15;25(14):4388-4399. doi: 10.1158/1078-0432.CCR-18-2575. Epub 2019 Apr 24.

PMID:
31018922
20.

Exophiala dermatitidis Fungemia Diagnosed Using Time-of-flight Mass Spectrometry during Chemotherapy for Malignant Lymphoma and Successful Treatment with Voriconazole.

Yoshida T, Tachita T, Fujinami H, Oshima Y, Sasaki H, Marumo Y, Narita T, Ito A, Ri M, Kusumoto S, Ishida T, Komatsu H, Iida S.

Intern Med. 2019 Aug 1;58(15):2219-2224. doi: 10.2169/internalmedicine.2082-18. Epub 2019 Apr 17.

21.

JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-2. Related disorders of multiple myeloma.

Iida S, Shimazaki C, Abe M, Nakaseko C.

Int J Hematol. 2019 Jun;109(6):633-640. doi: 10.1007/s12185-019-02640-y. Epub 2019 Apr 8. No abstract available.

PMID:
30963472
22.

JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM).

Iida S, Ishida T, Murakami H, Ozaki S, Abe M, Hata H, Shimazaki C.

Int J Hematol. 2019 May;109(5):509-538. doi: 10.1007/s12185-019-02636-8. Epub 2019 Apr 4. Review. No abstract available.

PMID:
30949913
23.

Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation.

Sasaki H, Mitani S, Kusumoto S, Marumo Y, Asano A, Yoshida T, Narita T, Ito A, Yano H, Ri M, Ishida T, Komatsu H, Iida S.

Int J Hematol. 2019 Jul;110(1):119-123. doi: 10.1007/s12185-019-02628-8. Epub 2019 Mar 16.

PMID:
30879266
24.

Multimodal Structural Distribution of the p53 C-Terminal Domain upon Binding to S100B via a Generalized Ensemble Method: From Disorder to Extradisorder.

Iida S, Kawabata T, Kasahara K, Nakamura H, Higo J.

J Chem Theory Comput. 2019 Apr 9;15(4):2597-2607. doi: 10.1021/acs.jctc.8b01042. Epub 2019 Mar 22.

PMID:
30855964
25.

A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress.

Saito S, Namisaki H, Hiraishi K, Takahashi N, Iida S.

Protein Sci. 2019 May;28(5):900-909. doi: 10.1002/pro.3598. Epub 2019 Mar 22.

26.

(2,5-Dioxoimidazolidin-4-ylidene)aminocarbonylcarbamic Acid as a Precursor of Parabanic Acid, the Singlet Oxygen-Specific Oxidation Product of Uric Acid.

Iida S, Yamamoto Y, Fujisawa A.

J Org Chem. 2019 Mar 15;84(6):3552-3558. doi: 10.1021/acs.joc.9b00163. Epub 2019 Mar 4.

PMID:
30807151
27.

Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents.

Mizuno S, Kawamura K, Hanamura I, Sunami K, Mori T, Nakamura F, Iida S, Nakazawa H, Makita M, Kako S, Sawa M, Ueda Y, Takahashi H, Kanda Y, Ichinohe T, Atsuta Y, Takamatsu H, Takami A.

Bone Marrow Transplant. 2019 Feb 19. doi: 10.1038/s41409-019-0478-4. [Epub ahead of print]

PMID:
30783208
28.

[A Case of Unresectable Pancreas Cancer with 32 Months Survival after Chemotherapy].

Amagasa H, Fukuda A, Yamada A, Kakuta R, Kajiyama D, Kawaguchi M, Shibuya G, Maeda S, Motoyama K, Ganno H, Imai K, Ami K, Iida S, Andou M.

Gan To Kagaku Ryoho. 2018 Dec;45(13):2417-2419. Japanese.

PMID:
30692483
29.

Peristomal Moisture-Associated Skin Damage and Independence in Pouching System Changes in Persons With New Fecal Ostomies.

Nagano M, Ogata Y, Ikeda M, Tsukada K, Tokunaga K, Iida S.

J Wound Ostomy Continence Nurs. 2019 Mar/Apr;46(2):137-142. doi: 10.1097/WON.0000000000000491.

30.

Development of a Novel Model of Central Retinal Vascular Occlusion and the Therapeutic Potential of the Adrenomedullin-Receptor Activity-Modifying Protein 2 System.

Hirabayashi K, Tanaka M, Imai A, Toriyama Y, Iesato Y, Sakurai T, Kamiyoshi A, Ichikawa-Shindo Y, Kawate H, Tanaka M, Dai K, Cui N, Wei Y, Nakamura K, Iida S, Matsui S, Yamauchi A, Murata T, Shindo T.

Am J Pathol. 2019 Feb;189(2):449-466. doi: 10.1016/j.ajpath.2018.10.021. Epub 2019 Jan 15.

PMID:
30658846
31.

The Elimination of Dental Crowding and Development of a Proper Dental Arch by Maxillary Anterior Segmental Distraction Osteogenesis for a Patient With UCLP.

Tanikawa C, Lee D, Oonishi YY, Haraguchi S, Aikawa T, Kogo M, Iida S, Yamashiro T.

Cleft Palate Craniofac J. 2019 Aug;56(7):978-985. doi: 10.1177/1055665618821831. Epub 2019 Jan 9.

PMID:
30626201
32.

Long-Term Developmental Process of the Human Cortex Revealed In Vitro by Axon-Targeted Recording Using a Microtunnel-Augmented Microelectrode Array.

Shimba K, Sakai K, Iida S, Kotani K, Jimbo Y.

IEEE Trans Biomed Eng. 2019 Sep;66(9):2538-2545. doi: 10.1109/TBME.2019.2891310. Epub 2019 Jan 7.

PMID:
30624211
33.

Weight control before and during pregnancy for patients with gestational diabetes mellitus.

Yasuda S, Iuchi T, Goto A, Katanoda K, Iida S, Oikawa Y, Namba A, Isshiki M, Inoue I, Kamei Y, Shimada A, Noda M.

J Diabetes Investig. 2019 Jul;10(4):1075-1082. doi: 10.1111/jdi.12989. Epub 2019 Jan 11.

34.

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group.

Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10.

PMID:
30545780
35.

[Safety and management of adverse events of ixazomib/lenalidomide/dexamethasone therapy in Japanese patients with relapsed/refractory multiple myeloma].

Iida S, Izumi T, Aotsuka N, Komeno T, Ishida T, Sunami K, Handa H, Berg D, Kase Y, Soeda J.

Rinsho Ketsueki. 2018;59(11):2399-2407. doi: 10.11406/rinketsu.59.2399. Japanese.

PMID:
30531133
36.

RAMP3 deficiency enhances postmenopausal obesity and metabolic disorders.

Liu T, Kamiyoshi A, Tanaka M, Iida S, Sakurai T, Ichikawa-Shindo Y, Kawate H, Hirabayashi K, Dai K, Cui N, Tanaka M, Wei Y, Nakamura K, Matsui S, Yamauchi A, Shindo T.

Peptides. 2018 Dec;110:10-18. doi: 10.1016/j.peptides.2018.10.006. Epub 2018 Oct 29.

PMID:
30385288
37.

Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.

Xu XS, Dimopoulos MA, Sonneveld P, Ho PJ, Belch A, Leiba M, Capra M, Gomez D, Medvedova E, Iida S, Min CK, Schecter J, Jansson R, Zhang L, Sun YN, Clemens PL.

Adv Ther. 2018 Nov;35(11):1859-1872. doi: 10.1007/s12325-018-0815-9. Epub 2018 Oct 29.

38.

Peritransplant VLA-4 blockade inhibits endogenous memory CD8 T cell infiltration into high-risk cardiac allografts and CTLA-4Ig resistant rejection.

Iida S, Miyairi S, Su CA, Abe T, Abe R, Tanabe K, Dvorina N, Baldwin WM 3rd, Fairchild RL.

Am J Transplant. 2019 Apr;19(4):998-1010. doi: 10.1111/ajt.15147. Epub 2018 Nov 26.

PMID:
30372587
39.

Utility of Laparoscopic Uterine Myomectomy as a Treatment for Infertility with No Obvious Cause Except for Uterine Fibroids.

Kameda S, Toyoshima M, Tanaka K, Fujii O, Iida SI, Yaegashi N, Murakami T, Hoshi K.

Gynecol Minim Invasive Ther. 2018 Oct-Dec;7(4):152-155. doi: 10.4103/GMIT.GMIT_2_18. Epub 2018 Sep 26.

40.

5-N-Carboxyimino-6-N-chloroaminopyrimidine-2,4(3H)-dione as a hypochlorite-specific oxidation product of uric acid.

Iida S, Yamamoto Y, Susa C, Tsukui K, Fujisawa A.

J Clin Biochem Nutr. 2018 Sep;63(2):85-89. doi: 10.3164/jcbn.18-6. Epub 2018 Jul 11.

41.

PHD3 regulates glucose metabolism by suppressing stress-induced signalling and optimising gluconeogenesis and insulin signalling in hepatocytes.

Yano H, Sakai M, Matsukawa T, Yagi T, Naganuma T, Mitsushima M, Iida S, Inaba Y, Inoue H, Unoki-Kubota H, Kaburagi Y, Asahara SI, Kido Y, Minami S, Kasuga M, Matsumoto M.

Sci Rep. 2018 Sep 24;8(1):14290. doi: 10.1038/s41598-018-32575-z.

42.

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ.

Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.

43.

A3 adenosine receptor agonist attenuates neuropathic pain by suppressing activation of microglia and convergence of nociceptive inputs in the spinal dorsal horn.

Terayama R, Tabata M, Maruhama K, Iida S.

Exp Brain Res. 2018 Dec;236(12):3203-3213. doi: 10.1007/s00221-018-5377-1. Epub 2018 Sep 11.

PMID:
30206669
44.

Living Related Renal Transplantation Using a Saphenous Vein Graft: A Case Report.

Shimizu T, Omoto K, Iida S, Inui M, Tsukuda F, Toma H, Iizuka J, Ishida H, Tanabe K.

Transplant Proc. 2018 Oct;50(8):2562-2564. doi: 10.1016/j.transproceed.2018.03.089. Epub 2018 Mar 19.

PMID:
30173850
45.

Cathepsin K inhibitor causes changes in crystallinity and crystal structure of newly-formed mandibular bone in rats.

Yoshioka Y, Yamachika E, Nakanishi M, Ninomiya T, Nakatsuji K, Kobayashi Y, Fujii T, Iida S.

Br J Oral Maxillofac Surg. 2018 Oct;56(8):732-738. doi: 10.1016/j.bjoms.2018.08.003. Epub 2018 Aug 18.

PMID:
30131193
46.

Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus.

Ikeda S, Takano Y, Schwab D, Portron A, Kasahara-Ito N, Saito T, Iida S.

Drug Res (Stuttg). 2019 Jun;69(6):314-322. doi: 10.1055/a-0662-0209. Epub 2018 Aug 13.

PMID:
30103216
47.

Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma.

Kinoshita S, Ishida T, Ito A, Narita T, Masaki A, Suzuki S, Yoshida T, Ri M, Kusumoto S, Komatsu H, Shimizu N, Inagaki H, Kuroda T, Scholz A, Ueda R, Sanda T, Iida S.

Haematologica. 2018 Dec;103(12):2059-2068. doi: 10.3324/haematol.2018.191395. Epub 2018 Aug 3.

48.

Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial.

Maruyama D, Tobinai K, Chou T, Taniwaki M, Shumiya Y, Iida S.

Cancer Sci. 2018 Oct;109(10):3245-3252. doi: 10.1111/cas.13753. Epub 2018 Sep 5.

49.

Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial.

Ohmachi K, Tobinai K, Kinoshita T, Ishikawa T, Hatake K, Ichikawa S, Ohmine K, Kamitsuji Y, Choi I, Chou T, Tsukasaki K, Kumagai K, Taniwaki M, Uchida T, Kikukawa Y, Kubo K, Mihara K, Tsukamoto N, Izutsu K, Yoshida I, Ishida F, Usui N, Iida S, Murayama T, Ueda E, Kuriki H, Ando K.

Int J Hematol. 2018 Nov;108(5):499-509. doi: 10.1007/s12185-018-2497-0. Epub 2018 Jul 19.

PMID:
30027429
50.

Clinical evaluation of a novel and highly sensitive immunoassay for anti-hepatitis B core antigen using a fully automated immunochemical analyzer.

Izumida K, Kaneko A, Takahashi K, Kusumoto S, Narita T, Takami A, Iida S, Aoyagi K, Tanaka Y.

Hepatol Res. 2018 Dec;48(13):1081-1091. doi: 10.1111/hepr.13229. Epub 2018 Aug 26.

PMID:
30006955

Supplemental Content

Support Center